JPRN-jRCT2051210197已完成1 期
ROH-202 ophthalmic solution phase I clinical trial -Single and multiple dose study
Kitano Takashi0 个研究点目标入组 48 人开始时间: 2022年3月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •Japanese healthy adult male, >=20 and <=45 of age, >=18.5 and <25.0 of BMI
排除标准
- •1) Subject with a serious history of eye, brain, liver, kidney, heart, lung, gastrointestinal, hematological, endocrine, metabolic, or neurological
- •2) Subjects with current or with a history of drug or alcohol abuse
研究者
相似试验
招募中
1 期
ROH-001 ophthalmic solution phase I clinical trial -Single and multiple dose studyHealthy volunteerJPRN-jRCT2051230128Mantani Tomomi48
进行中（未招募）
不适用
Phase 2 clinical trial of a gene therapy for choroideremiaEUCTR2015-001383-18-GBniversity of Oxford30
已完成
2 期
Clinical trial phase II of oral hebal compoenent (BMP) in patient with multiple sclerosisMultiple Sclerosis.Demyelinating diseases of the central nervous systemG35, G36,IRCT138803241696N2Iran Rheumatism Center10
进行中（未招募）
1 期
An open phase II study of safety, tolerability, highest tolerable dose and anti-tumor effect of SCO-101 in combination with FOLFIRI as a safe and effective treatment of patients with widespread colorectal cancer who has developed treatment resistance to treatment with FOLFIRIEUCTR2019-003779-20-ESScandion Oncology A/S35
进行中（未招募）
1 期
An open phase II study of safety, tolerability, highest tolerable dose and anti-tumor effect of SCO-101 in combination with FOLFIRI as a safe and effective treatment of patients with widespread colorectal cancer who has developed treatment resistance to treatment with FOLFIRIEUCTR2019-003779-20-DEScandion Oncology A/S35